A Phase 4 interventional study of Celecoxib and Celecoxib in Osteoarthritis, Knee and Osteoarthritis, Hip, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 124 sites in 8 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-03-29.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing celecoxib in Osteoarthritis, Knee — 1 open to participants now, 1 under way, none of them phase 3. Celecoxib · Osteoarthritis, Knee.
Among the 14 studies testing celecoxib in Osteoarthritis, Knee, this one has the largest enrollment, is the only one that started in 2005, is one of 10 in phase 4, and was the 2nd registered.
3,296 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.
Browse Osteoarthritis, Knee studies →1 of the 14 studies testing celecoxib in Osteoarthritis, Knee is open now, in 1 country. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 41+
By country, each count listing its studies:
Celecoxib: first FDA approval 1998 (CELEBREX), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 385 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 114 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 875 is above the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 216 across the 14 interventional studies. Of the 11 that completed or were terminated, 2 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 14 have an industry lead sponsor. The 8 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Viatris Inc. has 7 studies filed under Osteoarthritis, Knee — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing celecoxib in Osteoarthritis, Knee, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To determine whether "continuous use" of celecoxib over a 6-month period is more efficacious than "usual or intermittent use" in preventing spontaneous osteoarthritis flares of the knee and hip.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Celecoxib
Drug: Celecoxib
24 weeks of study treatment: 2 weeks open-label celecoxib 200 mg daily followed by 22 weeks of randomized double blind celecoxib 200 mg daily. Placebo used as flare medication when directed.
24 weeks of study treatment: 2 weeks open-label celecoxib 200 mg daily followed by 22 weeks of randomized double blind placebo daily. Usual or intermittent use of celecoxib 200 mg daily as flare medication when directed.
Number of Flare Events Per Time of Exposure to Study Medication
Number of flare events per month during Period III (calculated as number of flares divided by number of months participant was enrolled during Period III). Flare was determined using pre-defined criteria, using an interactive voice response system.
Time frame: Period III (22 weeks)
Time to Occurrence of First Osteoarthritis (OA) Flare
Time from first dose of double blind medication (start of Period III) to occurrence of first OA flare. Flare was determined using pre-defined criteria, using an interactive voice response system
Time frame: Period III (22 weeks)
Proportion of Days Free From Osteoarthritis (OA) Flare
Number of days subject was free from OA flare divided by number of days on study medication in Period III. Flare was determined using pre-defined criteria, using an interactive voice response system.
Time frame: Period III (22 weeks)
Proportion of Days in Osteoarthritis (OA) Flare
Number of days subject was in OA flare divided by number of days on study medication in Period III. Subjects may have more than one flare. Flare was determined using pre-defined criteria, using an interactive voice response system.
Time frame: Period III (22 weeks)
Arthritis Pain Numerical Rating Scale (NRS)
Participant rated intensity of osteoarthritis pain on categorical scale from 0 (no pain) to 10 (worst pain). Scores analyzed as area under the curve (AUC) of participant's scores from each assessment in Period III.
Time frame: Period III
Patient's Global Assessment of Arthritis
Participant's response to question "Considering all the ways the osteoarthritis in your hip or knee affects you, how are you doing today?" on scale from 1 (very good) to 5 (very poor). Scores analyzed as area under the curve (AUC) of participant's scores from each assessment in Period III.
Time frame: Period III
Physician's Global Assessment of Arthritis at Final Visit
Physician assessed each participant's disease symptoms on a categorical scale from 1 (very good) to 5 (very poor).
Time frame: Period III (22 weeks)
Total Rescue Medication Taken (Mean)
Total amount of rescue medication (acetaminophen in milligrams \[mg\]) taken per month per participant
Time frame: Period III (22 weeks)
Proportion of Days on Rescue Medication
Days on rescue medication divided by number of days on study medication in Period III
Time frame: Period III (22 weeks)
Days on Flare Medication
Number of days on flare medication per month per subject calculated as number of days on flare medication divided by the number of days on study medication in Period III
Time frame: Period III (22 weeks)
Change in Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Scores
Score at end of Period III minus score at start of Period III. WOMAC assesses subject responses to 24 components regarding subscales of pain, stiffness and physical function (score range: 0=none to 4= extreme). Total score is sum of the 3 subscale scores. Negative change indicates improvement.
Time frame: Period III (22 weeks)
Area Under the Curve (AUCs) of Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Scores
WOMAC assesses subject responses to 24 components regarding subscales of pain, stiffness and physical function (score range: 0=none to 4= extreme). Total score is sum of the 3 subscale scores. Scores analyzed as area under the curve (AUC) of participant's WOMAC scores from each assessment in Period III.
Time frame: Period III (22 weeks)
Change in Medical Outcomes Study Sleep Scale - All Assessments
Subject assessment on 7 sleep associated categories. Raw scores are transformed to a 0-100 scale. Higher score indicates more of the outcome (e.g. more snoring, more adequate sleep). Score at end of Period III minus score at start of Period III.
Time frame: Period III
Medical Outcomes Study Sleep Scale - Number of Participants With Optimal, Mixed and Not Optimal Sleep
Transformed score scale: 1=optimal; 0=not optimal; mixed = both optimal and non-optimal sleep during Period III
Time frame: Period III
Change in the Quality of Life Short Form-12v2 (SF-12v2) Scale Scores - All Assessments
SF-12v2 is a 12 item health survey covering 7 topics. Raw scores are transformed to a 0 to 100 scale. Higher scores indicate better state of health. Score at end of Period III minus score at start of Period III.
Time frame: Period III
Serious Adverse Events in Open Label run-in Period
Serious adverse events occuring during the 2 week run-in period (Period II) when all participants were dosed with celecoxib 200 mg daily
Time frame: 2 weeks prior to double blind dosing
111 centers in the Americas and Europe enrolled and treated subjects (2 centers in Belgium, 4 centers in Brazil, 20 centers in Canada, 5 centers in Chile, 5 centers in Columbia, 1 center in France, 15 centers in the United Kingdom, and 59 centers in the United States).
| Milestone | Wash-Out: Discontinue Non-Steroidal Anti-Inflammatories | Open-Label Celecoxib Run-in Period | Celecoxib 200mg Continuous Use | Celecoxib 200mg Intermittent Use |
|---|---|---|---|---|
| Started | 1772 | 0 | 0 | 0 |
| Completed | 1197 | 0 | 0 | 0 |
| Not completed | 575 | 0 | 0 | 0 |
| Withdrew: Did not enter period ii | 575 | 0 | 0 | 0 |
| Milestone | Wash-Out: Discontinue Non-Steroidal Anti-Inflammatories | Open-Label Celecoxib Run-in Period | Celecoxib 200mg Continuous Use | Celecoxib 200mg Intermittent Use |
|---|---|---|---|---|
| Started | 0 | 1197 | 0 | 0 |
| Completed | 0 | 875 | 0 | 0 |
| Not completed | 0 | 322 | 0 | 0 |
| Withdrew: Not randomized into period iii | 0 | 322 | 0 | 0 |
| Milestone | Wash-Out: Discontinue Non-Steroidal Anti-Inflammatories | Open-Label Celecoxib Run-in Period | Celecoxib 200mg Continuous Use | Celecoxib 200mg Intermittent Use |
|---|---|---|---|---|
| Started | 0 | 0 | 431 | 427 |
| Completed | 0 | 0 | 355 | 321 |
| Not completed | 0 | 0 | 76 | 106 |
| Withdrew: Adverse event | 0 | 0 | 22 | 23 |
| Withdrew: Other | 0 | 0 | 23 | 34 |
| Withdrew: Lack of efficacy | 0 | 0 | 10 | 24 |
| Withdrew: Lost to follow-up | 0 | 0 | 5 | 4 |
| Withdrew: Withdrawal by subject | 0 | 0 | 16 | 21 |
Number of flare events per month during Period III (calculated as number of flares divided by number of months participant was enrolled during Period III). Flare was determined using pre-defined criteria, using an interactive voice response system.
| flare events per month | Celecoxib 200mg Continuous Use | Celecoxib 200mg Intermittent Use |
|---|---|---|
| Number of Flare Events Per Time of Exposure to Study Medication | 0.54 ± 0.74 | 0.93 ± 1.01 |
Time from first dose of double blind medication (start of Period III) to occurrence of first OA flare. Flare was determined using pre-defined criteria, using an interactive voice response system
| days | Celecoxib 200mg Continuous Use | Celecoxib 200mg Intermittent Use |
|---|---|---|
| Time to Occurrence of First Osteoarthritis (OA) Flare | 16.0 (14.0 to 22.0) | 8.0 (8.0 to 9.0) |
Number of days subject was free from OA flare divided by number of days on study medication in Period III. Flare was determined using pre-defined criteria, using an interactive voice response system.
| proportion of days free from OA flare | Celecoxib 200mg Continuous Use | Celecoxib 200mg Intermittent Use |
|---|---|---|
| Proportion of Days Free From Osteoarthritis (OA) Flare | 0.77 ± 0.28 | 0.67 ± 0.30 |
Number of days subject was in OA flare divided by number of days on study medication in Period III. Subjects may have more than one flare. Flare was determined using pre-defined criteria, using an interactive voice response system.
| proportion of days in OA flare | Celecoxib 200mg Continuous Use | Celecoxib 200mg Intermittent Use |
|---|---|---|
| Proportion of Days in Osteoarthritis (OA) Flare | 0.23 ± 0.28 | 0.33 ± 0.30 |
Participant rated intensity of osteoarthritis pain on categorical scale from 0 (no pain) to 10 (worst pain). Scores analyzed as area under the curve (AUC) of participant's scores from each assessment in Period III.
| scores on a scale * weeks | Celecoxib 200mg Continuous Use | Celecoxib 200mg Intermittent Use |
|---|---|---|
| Week 4 (n=415 cont; n=414 inter) | 81.7 ± 1.1 | 90.5 ± 1.1 |
| Week 8 (n=401 cont; n=395 inter) | 148.8 ± 2.6 | 167.0 ± 2.6 |
| Week 12 (n=383 cont; n=363 inter) | 212.6 ± 4.1 | 234.3 ± 4.1 |
| Week 16 (n=373 cont; n=339 inter) | 272.7 ± 5.9 | 297.6 ± 5.9 |
| Week 20 (n=362; n=323 inter) | 335.9 ± 7.8 | 361.1 ± 7.8 |
| Week 24 (n=350 cont; n=403 inter) | 378.1 ± 9.1 | 403.9 ± 9.2 |
Participant's response to question "Considering all the ways the osteoarthritis in your hip or knee affects you, how are you doing today?" on scale from 1 (very good) to 5 (very poor). Scores analyzed as area under the curve (AUC) of participant's scores from each assessment in Period III.
| scores on a scale * weeks | Celecoxib 200mg Continuous Use | Celecoxib 200mg Intermittent Use |
|---|---|---|
| Week 4 (n=415 cont; n=414 inter) | 67.9 ± 0.68 | 71.7 ± 0.69 |
| Week 8 (n=401 cont; n=395 inter) | 126.0 ± 1.55 | 133.2 ± 1.56 |
| Week 12 (n=383 cont; n=363 inter) | 182.8 ± 2.48 | 188.7 ± 2.48 |
| Week 16 (n=373 cont; n=339 inter) | 236.3 ± 3.59 | 241.2 ± 3.59 |
| Week 20 (n=362 cont; n=323 inter) | 292.4 ± 4.83 | 293.8 ± 4.84 |
| Week 24 (n=350 cont; n=309 inter) | 329.2 ± 5.75 | 328.9 ± 5.76 |
Physician assessed each participant's disease symptoms on a categorical scale from 1 (very good) to 5 (very poor).
| participants | Celecoxib 200mg Continuous Use | Celecoxib 200mg Intermittent Use |
|---|---|---|
| Grade 1 (very good) | 68 | 39 |
| Grade 2 (good) | 242 | 244 |
| Grade 3 (fair) | 91 | 113 |
| Grade 4 (poor) | 23 | 27 |
| Grade 5 (very poor) | 2 | 2 |
Total amount of rescue medication (acetaminophen in milligrams \[mg\]) taken per month per participant
| mg taken per month per participant | Celecoxib 200mg Continuous Use | Celecoxib 200mg Intermittent Use |
|---|---|---|
| Total Rescue Medication Taken (Mean) | 1566 ± 4840 | 2428 ± 4974 |
Days on rescue medication divided by number of days on study medication in Period III
| proportion of days | Celecoxib 200mg Continuous Use | Celecoxib 200mg Intermittent Use |
|---|---|---|
| Proportion of Days on Rescue Medication | 0.044 ± 0.102 | 0.069 ± 0.121 |
Number of days on flare medication per month per subject calculated as number of days on flare medication divided by the number of days on study medication in Period III
| days on medication per month per subject | Celecoxib 200mg Continuous Use | Celecoxib 200mg Intermittent Use |
|---|---|---|
| Days on Flare Medication | 6.589 ± 8.589 | 9.793 ± 9.253 |
Score at end of Period III minus score at start of Period III. WOMAC assesses subject responses to 24 components regarding subscales of pain, stiffness and physical function (score range: 0=none to 4= extreme). Total score is sum of the 3 subscale scores. Negative change indicates improvement.
| scores on a scale | Celecoxib 200mg Continuous Use | Celecoxib 200mg Intermittent Use |
|---|---|---|
| Total WOMAC score | 1.60 ± 0.71 | 4.99 ± 0.71 |
| WOMAC pain subscale | 0.37 ± 0.15 | 1.18 ± 0.15 |
| WOMAC stiffness subscale | 0.12 ± 0.07 | 0.40 ± 0.07 |
| WOMAC physical function subscale | 1.13 ± 0.51 | 3.43 ± 0.51 |
Subject assessment on 7 sleep associated categories. Raw scores are transformed to a 0-100 scale. Higher score indicates more of the outcome (e.g. more snoring, more adequate sleep). Score at end of Period III minus score at start of Period III.
| scores on a scale | Celecoxib 200mg Continuous Use | Celecoxib 200mg Intermittent Use |
|---|---|---|
| Sleep disturbance (n=415 cont; n=410 inter) | 0.5 ± 15.95 | -1.4 ± 15.55 |
| Snoring (n=415 cont; n=412 inter) | 0.9 ± 22.36 | 0.7 ± 21.73 |
| Awaken short of breath (n=417 cont; n=411 inter) | 1.9 ± 16.14 | 1.1 ± 20.00 |
| Quantity of sleep (n=417 cont; n=413 inter) | -0.1 ± 0.91 | -0.1 ± 0.89 |
| Sleep adequacy (n=416 cont; n=413 inter) | 0.1 ± 24.47 | -1.3 ± 22.26 |
| Somnolence (n=416 cont; n=413 inter) | 1.4 ± 14.55 | 0.6 ± 13.70 |
| Sleep problems index I (n=416 cont; n=410 inter) | 0.9 ± 13.20 | 0.5 ± 13.18 |
| Sleep problems index II (n=413 cont; n=408 inter) | 0.7 ± 12.29 | -0.1 ± 12.14 |
WOMAC assesses subject responses to 24 components regarding subscales of pain, stiffness and physical function (score range: 0=none to 4= extreme). Total score is sum of the 3 subscale scores. Scores analyzed as area under the curve (AUC) of participant's WOMAC scores from each assessment in Period III.
| scores on a scale * weeks | Celecoxib 200mg Continuous Use | Celecoxib 200mg Intermittent Use |
|---|---|---|
| Total WOMAC score | 604.9 ± 313.10 | 693.6 ± 317.30 |
| WOMAC pain subscale | 119.2 ± 63.36 | 138.4 ± 65.95 |
| WOMAC stiffness subscale | 54.5 ± 27.57 | 62.1 ± 27.7 |
| WOMAC physical function subscale | 431.4 ± 229.38 | 493.6 ± 230.74 |
Transformed score scale: 1=optimal; 0=not optimal; mixed = both optimal and non-optimal sleep during Period III
| participants | Celecoxib 200mg Continuous Use | Celecoxib 200mg Intermittent Use |
|---|---|---|
| Optimal (all scores are 1) | 139 | 123 |
| Mixed (scores are both 1 and 0) | 166 | 165 |
| Not optimal (all scores are 0) | 115 | 132 |
SF-12v2 is a 12 item health survey covering 7 topics. Raw scores are transformed to a 0 to 100 scale. Higher scores indicate better state of health. Score at end of Period III minus score at start of Period III.
| scores on a scale | Celecoxib 200mg Continuous Use | Celecoxib 200mg Intermittent Use |
|---|---|---|
| Physical function (n=417 cont; n=413 inter) | 1.8 ± 23.03 | -3.2 ± 22.77 |
| Role physical (n=416 cont; n=412 inter) | 3.5 ± 19.93 | -1.1 ± 20.07 |
| Bodily pain (n=417 cont; n=414 inter) | 3.8 ± 20.11 | -0.3 ± 21.56 |
| General health (n=417 cont; n=414 inter) | -0.3 ± 17.60 | -0.8 ± 17.27 |
| Vitality (n=416 cont; n=414 inter) | 0.3 ± 20.43 | -3.5 ± 18.34 |
| Social functioning (n=416 cont; n=414 inter) | -1.9 ± 20.16 | -3.5 ± 22.37 |
| Role emotional (n=417 cont; n=413 inter) | -0.7 ± 18.62 | -2.1 ± 19.80 |
| Mental health (n=416 cont; n=413 inter) | -0.9 ± 15.57 | -1.3 ± 16.05 |
| Physical component summary(n=416 cont;n=411 inter) | 9.0 ± 55.55 | -5.2 ± 57.48 |
| Mental component summary (n=416 cont;n=411 inter) | -3.1 ± 51.59 | -10.5 ± 55.66 |
Serious adverse events occuring during the 2 week run-in period (Period II) when all participants were dosed with celecoxib 200 mg daily
| participants | Celecoxib 200mg Open Label |
|---|---|
| Anaemia | 1 |
| Vitreous haemorrhage | 1 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Celecoxib 200mg Continuous Use | — | — | — |
| Celecoxib 200mg Intermittent Use | — | — | — |
| Event | Celecoxib 200mg Continuous Use | Celecoxib 200mg Intermittent Use |
|---|---|---|
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/431 | 2/427 |
| Abdominal painGastrointestinal disorders | 0/431 | 1/427 |
| GastritisGastrointestinal disorders | 0/431 | 1/427 |
| PancreatitisGastrointestinal disorders | 0/431 | 1/427 |
| Chest painGeneral disorders | 1/431 | 1/427 |
| Non-cardiac chest painGeneral disorders | 0/431 | 1/427 |
| Skin lacerationInjury, poisoning and procedural complications | 0/431 | 1/427 |
| Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/431 | 1/427 |
| Transient ischaemic attackNervous system disorders | 0/431 | 1/427 |
| Bipolar I disorderPsychiatric disorders | 0/431 | 1/427 |
| Event | Celecoxib 200mg Continuous Use | Celecoxib 200mg Intermittent Use |
|---|---|---|
| HeadacheNervous system disorders | 65/431 | 68/427 |
| Back painMusculoskeletal and connective tissue disorders | 20/431 | 31/427 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 17/431 | 25/427 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 18/431 | 21/427 |
| NasopharyngitisInfections and infestations | 19/431 | 20/427 |
| Upper respiratory tract infectionInfections and infestations | 14/431 | 19/427 |
| DiarrhoeaGastrointestinal disorders | 7/431 | 17/427 |
| DyspepsiaGastrointestinal disorders | 17/431 | 6/427 |
| HypertensionVascular disorders | 9/431 | 13/427 |
| Oedema peripheralGeneral disorders | 4/431 | 12/427 |
| Age, Continuous(years) | Celecoxib 200mg Continuous Use | Celecoxib 200mg Intermittent Use | Total |
|---|---|---|---|
| Mean | 58.5 ± 10.00 | 58.7 ± 9.6 | 58.6 ± 9.8 |
| Sex: Female, Male(Participants) | Celecoxib 200mg Continuous Use | Celecoxib 200mg Intermittent Use | Total |
|---|---|---|---|
| Female | 317 | 303 | 620 |
| Male | 114 | 124 | 238 |
Showing the first 100 of 124 sites across 8 countries. Choose a country and city above to see the rest.
The record gives a start of Jul 2005, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.
Results were first posted in May 2009, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Celecoxib
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →